{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for beta root_references_citation in Reference Text / Citation (approximate match)
Status:
US Approved Rx
(1996)
Source:
BLA103628
(1996)
Source URL:
First approved in 1996
Source:
BLA103628
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1993)
Source:
BLA103471
(1993)
Source URL:
First approved in 1993
Source:
BLA103471
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03654508: Not Applicable Interventional Completed Asthma in Children
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:sampeginterferon beta-1a [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04456621: Not Applicable Interventional Completed Local Control Rate
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00791570: Phase 1 Interventional Completed Neovascular Maculopathy
(2008)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02384538: Phase 2 Interventional Completed Erosive Hand Osteoarthritis
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00781053: Phase 2 Interventional Completed Skin Fibrosis
(2008)
Source URL:
Class:
PROTEIN
Disitertide (P144) is a TGF-β1 antagonist peptide. Disitertide prevents TGF-β1-dependent inhibition of MV1Lu proliferation in vitro and markedly reduces binding of TGF-β1 to its receptors. P144 blocked TGF-beta1-dependent stimulation of a reporter gene under the control of human alpha2(I) collagen promoter. Intraperitoneal administration of P144 also showed potent antifibrogenic activity in vivo in the liver of rats receiving CCl4. These rats also showed a significant decrease in the number of activated hepatic stellate cells as compared with those treated with saline only. P144 decreased proliferation, migration, invasiveness, and tumorigenicity in vitro, whereas apoptosis and anoikis were significantly increased for glioblastoma cell lines. SMAD2 phosphorylation was reduced, together with a downregulation of SKI and an upregulation of SMAD7 at both transcriptional and translational levels. Additionally, P144 was able to impair tumor growth and increase survival in an in vivo flank model. This findings suggest a potential effect of P144 in vitro and in vivo that is mediated by regulation of transcriptional target genes of the TGF-β pathway, suggesting a therapeutic potential of P144 for glioblastoma treatment. Topical application of disitertide may promote scar maturation and clinical improvement of hypertrophic scar morphology features in an "in vivo" model in nude mice after two weeks of treatment.
